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Congenital lactic acidosis
PDHX
Roma/Gypsy founder mutationInvestigation of 31 of Roma patients with congenital lactic acidosis (CLA) from Bulgaria identiﬁed homozygosity
for the R446* mutation in the PDHX gene as the most common cause of the disorder in this ethnic group. It
accounted for around 60% of patients in the study and over 25% of all CLA cases referred to the National Genetic
Laboratory in Bulgaria. The detection of a homozygous patient from Hungary and carriers among population
controls from Romania and Slovakia suggests a wide spread of the mutation in the European Roma population.
The clinical phenotype of the twenty R446* homozygotes was relatively homogeneous, with lactic acidosis crisis
in the ﬁrst days or months of life as the most common initial presentation (15/20 patients) and delayed psycho-
motor development and/or seizures in infancy as the leading manifestations in a smaller group (5/20 patients).
The subsequent clinical picture was dominated by impaired physical growth and a very consistent pattern of
static cerebral palsy-like encephalopathy with spasticity and severe to profound mental retardation seen in
over 80% of cases. Most patients had a positive family history.
We propose testing for the R446* mutation in PDHX as a rapid ﬁrst screening in Roma infants with metabolic
acidosis. It will facilitate and accelerate diagnosis in a large proportion of cases, allow early rehabilitation to
alleviate the chronic clinical course, and prevent further affected births in high-risk families.
Crown Copyright © 2014 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Medical Research, Level 7, QQ
.
(L. Kalaydjieva).
r Inc. This is an open access article u1. Introduction
Pyruvate dehydrogenase is the rate-limiting enzymatic step that
links glycolysis to the tricarboxylic acid cycle and mitochondrial energy
metabolism [1]. The pyruvate dehydrogenase complex (PDC) consists of
three catalytic subunits (pyruvate dehydrogenase, E1; dihydrolipoamide
transacetylase, E2; dihydrolipoamidedehydrogenase, E3), two regulatory
subunits (E1 kinase and E1 phosphatase) and an E3-binding proteinnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Early clinical manifestations in PDHX p.Arg446* homozygotes.
Case no. Family Sex Birth Dysmorphic features Onset Metabolic data at onset Antenatal brain damage
At term BW
(g)
Age Manifestations Blood
lactate
mmol/l
Urine lactate
U/mol Cr
Alanine
μmol/l
Urine 2-HO—
butyrate U/mol Cr
Corpus callosum
hypo-/aplasia
Periventricular
cysts
Other lesions in the ﬁrst
3 weeks after birth
1 A M + 3000 Epispadias, inguinal
hernia
1 h Lactic acidosis
crisis
No data 27,780 3549 (P) 410 + − −
2 A M + 3000 − 8 d Lactic acidosis
crisis
No data 8002 2135 (P) 372 − − −
3 B# M + 3400 Ear malrotation,
low umbilicus
16 d Lactic acidosis
crisis
11.1 63 386 (DBS) 32 − + Ventricular dilatation
4 C# F + 3150 − 16 d Lactic acidosis
crisis
11.0 11,793 No data 2200 + + Ventricular dilatation
5 D F + 2850 − 17 d Lactic acidosis
crisis
No data 3764 1322 (P) 1025 − + Ventricular septi
6 E M No data 2480 − 20 d Lactic acidosis
crisis
13.3 380 1099 (DBS) 75 − − −
7 E M + 2400 − 23 d Lactic acidosis
crisis
15.0 425 639 (DBS) 82 − − −
8 D M + 2800 − 29 d Lactic acidosis
crisis
No data 12,989 No data 3035 + − −
9 F F + 3000 − 25 d Lactic acidosis
crisis
No data 4614 No data 78 − + −
10 G F + 3200 − 2 m Lactic acidosis
crisis
7.3 No data No data No data + − −
11 I# F + 3100 − 5 m Lactic acidosis
crisis
5.5 5584 No data 262 + − −
12 J M + 2800 Epicanthal folds 12 d Lactic acidosis
crisis
12.68 23,324 903 (P) 966 + + Ventricular dilatation
13 K F No data No
data
Facial
dysmorphism,
non-speciﬁed
2 m Lactic acidosis
crisis
No data 15,191 2942 (DBS) 838 + − −
14 L M + 2400 − 2 d Lactic acidosis
crisis
No data 3233 1072 (DBS) 482 − − Ventricular dilatation
15 M F + 3150 Hypertelorism,
epicanthal folds
20 d Vomiting,
seizures,
somnolence
No data at
onset
+ − −
16 M M + 3905 − 4 m Developmental
delay
No data at
onset
− − No data
17 N M + No
data
Short philtrum 6 m Developmental
delay, seizures
No data at
onset
− − No data
18 N F + No
data
Flat nasal bridge,
hypertelorism
3 m Developmental
delay, seizures
No data at
onset
− − No data
19 N M + 3050 Hypertelorism,
megalocornea
6 m Developmental
delay, seizures
No data at onset − − No data
20 O# F + No
data
− 6 m Developmental
delay
No data at
onset
No data
Legend: (+)— present; (−)— absent; # previous affected child deceased; BW— birthweight; h— hour, d— day,m—month, y— year; OH— hydroxy; DBS— dried blood spot; P— plasma; urinemetabolites are represented in relative units (U): ratio
of chromatographic peak area ofmetabolite to that of added internal standard (3-Phenylbutyric acid) permol creatinine (Cr). Reference ranges ofmetabolites: blood lactate b2.2 mmol/l; DBS alanine— 114–577 (newborn), 92–290 (1 m–1 y) μmol/l;
plasma alanine— 89–508 (newborn) μmol/l; urine lactate — 8–421 U/mol Cr; 2-hydroxybutyrate — 0–85 U/mol Cr.
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Fig. 1. Step-wise ﬁltering of the variants identiﬁed by WES.
78 I.S. Ivanov et al. / Molecular Genetics and Metabolism 113 (2014) 76–83(E3BP) that binds E2 to E3. PDC deﬁciency is amajor cause of congenital
lactic acidosis (CLA) that leads to failure in energy production and
developmental and encephaloclastic disorders of the central nervous
system (reviewed in [1,2] and recently in [3–5]). The incidence and
prevalence of PDC deﬁciency are not well deﬁned and the large number
of genes encoding PDC components implies mutation heterogeneity
that requires extensive biochemical and genetic work-up leading to
etiological diagnosis. Mutations in the PDHX gene, encoding E3BP,
are the second most common cause of PDC deﬁcit [3]. All are null-
mutations, conﬁned to individual families, that result in complete pro-
tein deﬁcit and substantial reduction of PDC activity (reviewed in [6,7]).
Here we report a founder mutation in the PDHX gene, explaining
over half of CLA cases in children of Roma ethnicity. We present data
on the phenotypic features and evolution of the disorder in 20 patients
homozygous for themutation, the largest group of genetically homoge-
neous affected subjects reported to date. Our ﬁndings provide a simple
test for fast-track diagnosis in this ethnic group that can substitute for
the lengthy process of clarifying the variable causes of metabolic crisis
in the newborn.Fig. 2. Sanger sequencing of PDHXwith the three c.1336CNT genotypes.2. Subjects and methods
2.1. Subjects
The study included 56 participants from 23 nuclear Roma families
from Bulgaria (3 of these belonged to an extended kindred): 31
individuals with diagnosed or suspected CLA and 25 healthy relatives.
Seventeen affected infants were referred by the Department of Pediatrics
and Medical Genetics at Plovdiv Medical University, and eight by the
National Genetic Laboratory. Six additional cases (four cousins and two
siblings from a different family), diagnosed as hereditary spastic paraple-
gia with mental retardation, were referred by the Neurology Department
of the Medical University-Soﬁa because of hyperlactataciduria detected
during previous hospital admissions in three of these patients. In the
course of the study, 21 CLA patients of unspeciﬁed ethnicity from
Hungary were tested for the presence of the PDHXmutation.
Written informed consent has been provided by all participating
subjects or their guardians. The study complies with the ethical guide-
lines of the institutions involved.Carrier frequency was estimated in a panel of 657 de-identiﬁed
ethnically matched controls and 53 exome controls, representing Roma
groups from the Balkan, Vlax and Central/West European migration
categories [8].
2.2. Clinical data
Clinical, metabolic, neurophysiological and imaging (brain ultra-
sound, CT and MRI) data were collected from hospital records and
during follow-up visits.
2.3. Biochemical analyses
Routine blood and urine analyses assessed blood, liver, and kidney
function. Urine organic acids were analyzed by gas chromatography–
mass spectrometry (Agilent Technologies 7890A GC/5975C MSD) after
organic solvent sample extraction with trimethylsilylation. Amino
acid analysis in dried blood spots was performed by electrospray
ionization–tandem mass spectrometry after organic solvent sample
extraction without derivatization, on aWaters TQ Detector equipped
with Waters 1526 μBinary HPLC Pump, using manufacturer kits
(Chromsystems). Plasma amino acids were analyzed by reversed
phase high performance liquid chromatography with ﬂuorescence
detection (Waters HPLC system). PDH complex enzyme activity
was measured in cultured skin ﬁbroblasts (patient 3) using 2 mg of
cell lysates with the PDH Enzyme Activity Microplate Assay Kit
(Abcam) following the manufacturer's instructions.
2.4. Genetic analyses
DNA was extracted from blood in most cases except 10 affected
infants, where archived urine (7 cases) or Guthrie cards (3 cases)
were the only available biological material.
Whole exome sequencing (WES)was performed at the University of
Queensland Centre for Clinical Genomics on DNA samples from three
trios and a singleton (affected child and parents from families A, B and
C and patient 7 in Table 1) from the Plovdiv sample.Weused the SeqCap
Roche Human Exome V3 capture system (Roche NimbleGen, Madison,
WI, USA) and the HiSeq2000 platform (Illumina, San Diego, CA, USA).
Initial data processing was done as described previously [9,10]. We
used 6491 markers, extracted from WES data at HapMap Phase II
SNP positions [10,11] to estimate inbreeding coefﬁcients [12] and
relatedness [13]. The search for the disease-causing mutation focused
on variantswith a quality score≥20 and coverage≥4×, located outside
of segmental duplications and simple repeats. The step-wise ﬁltering
79I.S. Ivanov et al. / Molecular Genetics and Metabolism 113 (2014) 76–83criteria included: a) allele frequency ≤1% in the 1000Genomes (http://
www.1000genomes.org/) or NHLBI (http://evs.gs.washington.edu/EVS/)
Exome Sequencing projects; b) “deleteriousness”predictions (Polyphen2
[14] scores N0.8 and SIFT [15] scores ≤0.05), splice-site (±15 nt), non-
sense, non-stop, and small in-frame or frame-shift in/dels; c) shared
homozygosity between affected individuals; d) heterozygosity of the
parents; e) no homozygous subjects in the in-house Roma control
exomes.
Mutation screening in the panel of population controlswas performed
with a custom-designed TaqMan® assay with forward and reverse
primers CCTCAGGCCTGCATTTTGG and CATTTCCCTCTTCATCCTCAGTGA,
respectively, and reporters CTTCAGCACAGGTCGGA and CTTCAGCACA
GGTCAGA. The heterozygotes identiﬁed by the screening assay were
conﬁrmed by Sanger sequencing.
Bidirectional Sanger sequencing of PCR-ampliﬁed fragments was
performed using BigDye terminator v3.1 (Applied Biosystems,
Mulgrave, VIC, Australia) with primers PDHXfwd AAGGACATGCCTCC
TTCAGA and PDHXrev TTCGTCATCAACCACTCGAC.
DNA fromurinewas obtained from50mlurine centrifuged at 1000 g
and the sediment stored and transported in Thermo Scientiﬁc™
AssayAssure™ Universal Urine Collection Tubes. DNA was extracted
using the QIAamp DNA Micro Kit (Qiagen, VIC, Australia).
3. Results
3.1. Genetic ﬁndings
3.1.1. WES data analysis reveals inbreeding and identiﬁes a truncating
mutation in PDHX
The F coefﬁcients of the four affected individuals with exome data
were estimated at 0.040–0.079, corresponding to the offspring of 1st
cousins to 1st cousins once removed. Relatedness analysis revealed
distant relationships, 2nd cousins or lower between parents within
and between families (mean proportion of alleles identical by descent
0.029 ± 0.0106).
Based on the common origins and evidence of inbreeding, our
search for the disease-causing mutation was based on the assumption
of shared homozygosity for a rare pathogenic variant. Exome-wide, a
single variant passed all ﬁltering criteria (Fig. 1): NM_003477.2:
c.1336CNT in the PDHX gene, predicted to result in a premature termi-
nation codon in the last exon, p.Arg446*.
Sanger sequencing (Fig. 2) conﬁrmed the WES ﬁndings: the four
patients were homozygous for the mutation and the six parents were
carriers.
3.1.2. p.Arg446* is a founder mutation that explains 60%
of cases of congenital lactic acidosis in Roma children
Mutation screening of 710 population controls identiﬁed ﬁve
carriers, three from Balkan Roma groups in Bulgaria, and one each
from Romania and Slovakia, translating to an overall carrier rate of
about 1 in 150 individuals in the general Roma population. Noheterozy-
gotes were detected among the Vlax Roma in Bulgaria.
Next, we used Sanger sequencing to examine the presence of the
p.Arg446* mutation in the entire group of affected individuals and
their relatives. Homozygosity for the mutation was revealed in 19 out
of the 31 Roma patients from Bulgaria, thus explaining around 60% of
congenital lactic acidosis in this ethnic group. One homozygote was
also detected in the Hungarian sample, but further conclusions on its
frequency cannot be drawn due to the lack of data on ethnicity.
The 20 p.Arg446* homozygous patients belonged to 15 nuclear
families, two of which were related (family N in Table 1). Five families
were represented by sib pairs; patient 19 and siblings 17 and 18 from
family N were 1st cousins once removed. Of the remaining nine cases,
four had a deceased affected sibling. Thus 9/14 families had more than
one affected child (Table 1).The residual group of mutation-negative patients reveals genetic
heterogeneity. One affected child with typical manifestations of neona-
tal onset lactic acidosis crisis was found to be a p.Arg446* carrier, a coin-
cidentalﬁnding that cannot explain the disease. Heterogeneity can exist
evenwithin the same extended family: in family N, 3/4 affected cousins
were p.Arg446* homozygots while the fourth was not even a carrier.
The mutations in this group of patients await clariﬁcation.
3.2. Clinical features
3.2.1. Lactic acidosis crisis in infancy was the most common
initial presentation
The ﬁndings are summarized in Table 1. The predominant clinical
phenotype was that of a lactic acidosis crisis occurring in the newborn
period (11 cases) or early infancy (3 cases). Both sexes were equally
represented. Patient no. 15 is likely to belong to this group as well,
based on onset with vomiting, seizures and somnolence, however
no further analyses were performed at the time. In this patient,
hyperlactataciduria (1529 U/mol Cr) and hyperalaninemia (852 μmol/l)
were ﬁrst determined at age 1 y 9 m.
The presenting symptoms in this group were variable combinations
of vomiting, failure to thrive, apnea/grunting, hypotonia, seizures,
stupor and coma. In 5 cases the metabolic crisis had been provoked by
infection. Upon admission, all patients had decompensated metabolic
acidosis (pH 6.9 to 7.36, BE values−4.7 to−22). Blood lactate levels
varied between 5.5 and 15 mmol/l, urine excretion of lactate and
2-hydroxybutyric acid ranged from borderline to massive, with
variable increased excretion of Krebs cycle metabolites, and ketoacids
found occasionally. Blood amino acid analysis showed the invariable
presence of hyperalaninemia. Non-speciﬁc pathological ﬁndings
commonly includedproteinuria andhematuria. PDC activity inﬁbroblasts
was 20% of control values. Data on pyruvate concentrations were not
available.
In a smaller group of patients (nos. 16 to 20), the reason for seeking
medical attention included delayed psychomotor development and/or
seizures at age 3–6 months. In this group, hyperlactatemia had been
diagnosed at a later age (patients 17,18, 20).
While all children had been born at term, birth weight (2980.31 ±
379.76 g) was below the population mean (4000 ± 600 g male
and 3700 ± 600 female) [16]. Microcephaly (head circumference b X−
2 SD) in the neonatal period was observed in 6 (nos. 2, 3, 6, 7, 9, and
15) out of 7 children with available head circumference data from that
period.
Variableminormalformations or dysmorphic features of no consistent
pattern were described in 8 patients (5 male).
Antenatal brain damage was commonly observed — found in 12 of
the 15 patients where data were available. Aplasia or hypoplasia of
corpus callosum was the most consistent abnormality, found in 8
children (5 females). Other common ﬁndings included periventricular
cysts and atrophic ventricular dilatation.
3.2.2. Intellectual deﬁcit and spasticity dominate the evolution
of the disease
The phenotypic features beyond the ﬁrst months of life are summa-
rized in Table 2.
Most affected children survived infancy. Death occurred during the
ﬁrst year of life in two patients, another died at age 11 y, and a fourth
patient died at an unspeciﬁed age. The oldest living patients in the
study were 22 and 25 y old.
Physical development was impaired in most cases, affecting height,
weight and head circumference. Microcephaly was present in 10 of
the 14 children with known last visit measurements. Mean head
circumference was X− 3.50 SD.
The frequency of lactic acidosis crises decreased gradually, with
none registered after age 5 y. Moderate hyperlactacidemia persisted
with values ranging between 2.3 and 5.5 mmol/l in nine children for
Table 2
Phenotype evolution in patients homozygous for PDHX p.Arg446*.
Case
#
Physical development (SD) Neurological ﬁndings
Age at most
recent
clinical
assessment
Height Weight Head
circumference
Intellectual
development
DQ/IQ
Motor Dystonia/
chorea
Epileptic seizures Visual
pursuit
Hearing
(audiopalpebral
reﬂex)
Postnatal chronic brain lesions Blood
lactate
(mmol/
l)/at age
1 9 y −1.31 −0.83 −2.01 21 Spastic
diplegia
Focal
paroxysmal,
since 3 y
Neonatal seizures; EEG: biF &
generalized SW at 5 y, normal at
6 & 8 y
+ + Bilateral hyperintense lesions in globus pallidus, cortical
and periventricular brain atrophy, frontal and occipital
periventricular leukoencephalopathy at 5 and 8 y on MRI
3.5/5 y
3 m
2 Died at 32 d
3 4 y −0.22 −1.82 −2.67 25 Spastic
quadriparesis
− GTCS at 12 m; EEG: abnormal
background activity at 1 & 2 y
+ + Cortical and periventricular brain atrophy after 4 m on US 4.7/2 y
8 m
4 5 y −3.85 −4.45 −12.2 6 Spastic
quadriparesis
− SGTCS since 11 m; EEG: R F slow
SW at 5 m, multifocal SW at 2 y
− − Hyperechogenicity of basal ganglia and cortical and
periventricular brain atrophy after 3 m on US
No data
5 Died, age
unspeciﬁed
No data No
data
No data “Low” Spastic
quadriparesis
− GTS; EEG: burst-suppression
pattern
No
data
No data Multicystic encephalomalacia after 22 d on US 2.94/8 m
6 2 y −3.99 −3.81 −4.41 29 Hypotonia − No seizures; EEG: abnormal
background activity at 8 m
− + Cortical and periventricular brain atrophy after 1 m on US No data
7 4 y −2.96 −2.56 −3.46 25 Hypotonia − SGCS & infantile spasms at 2 y;
EEG: normal at 8 m, multifocal
SW 2 y, R C–T SW at 5 y
− + Cortical and periventricular brain atrophy after 4 m on US
and MRI; normal MR spectroscopy at 1 y
2.74/2 y
4 m
8 9 y −3.43 −1.89 −0.44 b20 Spastic
diplegia
Frequent
short
dystonic
postures
No seizures; EEG: low voltage at
1 m, C–T SW at 9 y
+ + Cortical and periventricular brain atrophy after 1 m on
US; periventricular leukoencephalopathy at 9 y on MRI
2.3/9 y
9 14 y No
data
b11 Spastic
quadriparesis
− Neonatal seizures, no data after
5 m; EEG: biF & R C sharp waves
at 1 m; hypsarrhythmia at 5 m
No
data
No data Cortical and periventricular brain atrophy after 5 m on US No data
10 7 y −2.39 −1.09 −3.01 b30 Spastic
diplegia
Hemi-
dystonic
(R N L),
since 5 y
SGTCS at 5 y; EEG: normal at 5 &
6 y; rhythmic theta at 7 y
+ + Hyperechogenicity of basal ganglia; cortical and
periventricular brain atrophy after 2 m on US
2.6/7 y
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Case
#
Physical development (SD) Neurological ﬁndings
Age at most
recent
clinical
assessment
Height Weight Head
circumference
Intellectual
development
DQ/IQ
Motor Dystonia/
chorea
Epileptic seizures Visual
pursuit
Hearing
(audiopalpebral
reﬂex)
Postnatal chronic brain lesions Blood
lactate
(mmol/
l)/at age
11 10 y −5.6 −3.13 −7.54 5 Spastic
quadriparesis
− SGTCS since 5 m; EEG: L C–P–T
SW at 5 y; R C–P–O spikes and
SW at 10 y
+ + Cortical and periventricular brain atrophy at 10 y on MRI 5.5/10 y
12 Died at 40 d
13 No data
14 1 y 1 m No data −1.4 −1.5 30 Spastic
quadriparesis
− PMS and GTCS since 6 m; EEG
normal at 1 y
+ + Periventricular brain atrophy at 10 m on CT scan No data
15 1 y 6 m died
11 y
−1.8 −0.5 −1.9 b30 Spastic
quadriparesis
− Infantile spasms; EEG: R P sharp
waves
+ + Cortical atrophy at 4 m on CT; Cortical and
periventricular brain atrophy and subcortical
leukoencephalopathy at 7 y on MRI
No data
16 1 y No data +0.25 −0.5 b30 Spastic
quadriparesis
− − + + Cortical and periventricular brain atrophy at 1 y on CT No data
17 14 y
25 y
−2.44–
2.54
−2.9 −2.7–2.8 b30 Spastic
quadriparesis
− GTCS since 6 m; EEG: abnormal
slow background activity at 14 y
+ + Cortical and periventricular brain atrophy and subcortical
leukoencephalopathy at 14 y on MRI
3.14/14 y
18 11 y
22 y
−2.75–
2.80
−2.2 −4.4–4.5 b20 Spastic
quadriparesis
− GTCS between 3 m and 5 y;
EEG: abnormal slow background
activity at 11 y
+ + Cortical and periventricular brain atrophy,
periventricular leukoencephalopathy at 11 y on MRI
4.06/11 y
19 4 y +1.0 No
data
−2.2 b30 Axial
hypotonia
Choreiform
movements
in the UL
CPS and SGTCS since 2 y − + Cortical brain atrophy at 3 y on CT No data
20 4 y No data No
data
No data b30 Spastic
quadriparesis
− − + No data No data No data
Legend: (+)— present; (−)— absent; R— right, L— left, UL— upper limbs, d— day, m—month, y— year, F— frontal, C— central, P— parietal, C–T— centrotemporal, C–P–T— centroparietotemporal, C–P–O— centroparietooccipital, CPS— complex
partial seizures, GTCS — generalized tonic clonic seizures, SGTCS — secondary generalized tonic clonic seizures; US — brain ultrasound.
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test [17] performed in 7 children (nos. 1, 3, 4, 6, 7, 8, 11) showed a
reliable blood lactate increase in all.
The clinical phenotype was dominated by central nervous system
signs. Intellectual deﬁcit was invariably present, ranging from severe
to profound. Spasticity was a typical ﬁnding, observed in 14 of the 17
cases where information was available. Dystonic attacks were rare,
and present in only three patients with cerebral palsy (CP)-like motor
abnormalities.
Four patients were virtually blind (nos. 4, 6, 7 and 19). Visual evoked
potentials were tested in three patients and were abnormal in two
(nos. 5 and 6) and normal in patient nos. 7 at age 7m. No abnormalities
in eye fundiwere detected in any of the16patients examined. Abnormal
hearing, clinically or on brainstem auditory evoked response, was found
in 4 patients (nos. 2, 4, 5 and 6).
Epileptic seizures were observed in 13 patients; two (nos. 6 and 8)
had abnormal EEG recordings without history of seizures.
EMG, performed in four patients, showed axonal neuropathy at 8 y
in patient no. 1 after being normal at 5 y, myopathic changes in patient
no. 11 at 10 y, and normal ﬁndings in patient nos. 7 at 2 y and no. 15 at
7 y. No EMG data are available for patient 19, who presented with
generalized hyporeﬂexia.
Cortical brain atrophy and ventricular enlargement were the
dominant postnatal brain lesions, observed in 15 patients. Basal ganglia
involvement was found in three patients.
4. Discussion
PDHX defects are the secondmost common cause of CLA after PDHA1
mutations, yet the overall number of published cases is less than 30,
with diverse mutations and ethnic origins (most recently reviewed in
[7]). Here, we present a genetically homogeneous group of 20 Roma
patients homozygous for a single ancestral mutation in the PDHX
gene, p.Arg446*. The age range of the patients and the availability of
clinical information at various time points allowed us to summarize
the pattern of presentation and evolution of the disease (Table 3).
The phenotype was relatively homogeneous with no obvious differ-
ences between the sexes. Antenatal brain damage and microcephaly
were common ﬁndings. The presentation was usually emergency
hospitalization due to lactic acidosis crisis in the ﬁrst days or months
of life. Most patients survived into childhood. The subsequent clinical
picture was that of impaired physical growth and a consistent pattern
of static cerebral palsy-like encephalopathy with spasticity and severe
to profound mental retardation. Epileptic seizures occurred in over
half of cases. Sensory impairment (vision and auditory function) was
relatively common. While no acute/recurrent episodes of brainstem
dysfunction were documented, six patients (Table 2) developed signs
and symptoms consistent with Leigh syndrome: neuroimaging evidence
of basal ganglia involvement in three subjects, muscle hypotonia in
three, andmovement disorders in four (dystonia in three and choreiform
movements in one). Mild axonal neuropathy was found in one patient.
Relapsing ataxia was altogether absent.
The clinical features of our p.Arg446* homozygotes agreewith previ-
ously published ﬁndings in patients with PDHXmutations (reviewed in
[5–7,18]) as regards onset in the ﬁrst months of life with lactic acidosis,
survival beyond the 1st year and psychomotor retardation. The unifor-
mity and characteristics of the neurological phenotype in our patients
contrast with other studies. CP-like spasticity was present in 14/17 of
our cases, but was relatively rare in other descriptions: 0/19 patients
[6], 2/11 [18] and 4/24 [7], with the exception of [5] where 5/5 patients
displayed a CP-like clinical picture with dystonia. Еpileptic seizures
were also more common, occurring in 13/16 of our patients, while in
only 4/19 patients [6], 2/11 [18], 2/5 [5] or 4/24 cases [7].
The p.Arg446* mutation has been reported previously in three
patients of unspeciﬁed ethnicity in the UK and France [6,7]. It would
be of interest to know if these are Roma or Indian/Pakistani families
83I.S. Ivanov et al. / Molecular Genetics and Metabolism 113 (2014) 76–83sharing the same ancestral mutation, as shown in other disorders [19].
Our study shows that PDHX p.Arg446* is the major cause of primary
lactic acidosis in Roma children. It accounted for around 60% of affected
subjects in the study and for 27% of a total of 69 cases of lactic acidosis
(regardless of ethnicity) referred to the National Genetic Laboratory
during the period 1996–2013. While the overall carrier rate is not
high compared to other recessive founder mutations in the Roma [19],
the detection of an affected homozygote in Hungary and of carriers in
Romania and Slovakia indicates that the mutation is wide spread and
that affected births can occur anywhere in Europe. The ﬁnding of
relatedness between affected families that are unaware of each other's
existence points to local founder effect and on-going inbreeding leading
to increased risk in some Roma communities. Inter-family relatedness,
which we have not observed in other studies [13], may also contribute
to the homogeneity and characteristic features of the phenotype — in
addition to being homozygous for the same ancestral mutation, the
patients are more likely to share a similar genetic background.
Establishing the cause ofmetabolic acidosis in a critically ill newborn
involves a series of metabolic analyses, followed in the case of lactic
acidosis by measurements of PDC activity, protein levels of its subunits
and sequencing of the gene(s) presumed to be involved. Given the
high proportion of PDHX p.Arg446* homozygotes among Roma babies
with lactic acidosis, we propose mutation testing as a ﬁrst-tier shortcut
that can greatly simplify and facilitate the diagnosis and allow early
dietary and rehabilitation measures to alleviate the severely disabling
subsequent chronic course of the disease. Although the efﬁcacy of dietary
treatment in PDHc deﬁcit has not been documented in prospective
controlled trials [3], a beneﬁcial effect of ketogenic diet on childhood
epilepsy and paroxysmal dystonia has been reported in patients with
PDHXmutations [5,6,20]. In addition to the correction of acidosis during
the early LA crises in infancy, the introduction of a ketogenic diet may
modify the clinical course of the disease, at least in patients that have
the above neurological manifestations. Early initiation of rehabilitation
measures is at least as important, given the high frequency of spasticity
in the CP-like phenotype.
Further, the early diagnostic “clue” of lactic acidosis attacks is
gradually lost in early childhood (this study, [7,21]) and replaced by
non-speciﬁc phenotypic features that make the metabolic and genetic
diagnosis more problematic and easier to miss. Including the p.Arg446*
mutation in the diagnostic workup of the Roma patient with growth
retardation, “cerebral palsy” and mental retardation may not give a
high yield of positive results, but will speed up the procedure in some
cases and, with time, will provide information on the contribution of
CLA to the poorly deﬁned category of “cerebral palsy” in this ethnic
group. Furthermore, over 60% of families participating in this study had
more than one affected child. Early selective screeningwill allow genetic
counseling and help the prevention of further affected births.
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